Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study

Lee, Dong Seok; Kim, Ji Won; Lee, Kook Lae; Jung, Yong Jin; Kang, Hyoun Woo

doi:10.1016/j.ijid.2022.03.007

Cited by 19 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AZD122 resulted in more adverse reactions after vaccination than BNT162b2. These results were quite similar to those from our previous study [ 22 ].…”

Section: Discussionsupporting

confidence: 93%

“…First, it was a retrospective single-center study with a small sample size. Considering the results of our previous study [ 22 ], actual adverse events may have a higher incidence. Second, there could be difficulties in defining the causal–temporal relationship between COVID-19 vaccination and several complications.…”

Section: Discussionmentioning

confidence: 97%

“…Other symptoms such as dyspnea, generalized weakness, headache, and decreased consciousness levels were considered additional symptoms. Patients were classified into three groups based on disease severity according to the Korean Food and Drug Administration guidelines regarding symptoms, laboratory results, medical treatment, hospitalization, and recovery period [ 21 , 22 ]. Patients in the mild group had stable vital signs and normal C-reactive protein (CRP) levels, whereas those in the moderate group had stable vital signs and abnormal CRP levels; they required medical treatment.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study

Lee¹,

Kim²,

Lee³

et al. 2022

The American Journal of Emergency Medicine

Self Cite

View full text Add to dashboard Cite

“…AZD122 resulted in more adverse reactions after vaccination than BNT162b2. These results were quite similar to those from our previous study [ 22 ].…”

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 97%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study

Lee¹,

Kim²,

Lee³

et al. 2022

The American Journal of Emergency Medicine

Self Cite

View full text Add to dashboard Cite

“…The frequency of VITT reports is about 40 folds greater than that shown in Comirnaty recipients. Similar results were found in South Korea ( 38 ) even if the incidence of VITT in Vaxzevria recipients was lower than that observed in EEd.…”

Section: Venous Thrombosis In Recipients Of Adenovirus-based Vaccinessupporting

confidence: 86%

“…Thus, the difference in the incidence of VITT after the Vaxzevria vaccine in South Korea compared with Europe may be due, at least in part, to the age of vaccinee. In fact, in South Korea only 18.3% of the vaccinated people were under 50 years of age, whereas in Europe, these were 37.1% of the population ( 38 , 39 ).…”

Section: Venous Thrombosis In Recipients Of Adenovirus-based Vaccinesmentioning

confidence: 99%

Thrombotic events with or without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines

Cari

Alhosseini

Bergamo

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

COVID-19, the severe acute respiratory syndrome, is one of the major emergencies that have affected health care systems. Drugs and oxygen are only partially effective in saving lives in patients with severe COVID-19, and the most important protection from death is vaccination. The widespread use of COVID-19 adenovirus-based vaccines has provided evidence for the occurrence of rare venous thrombotic events including cerebral venous thrombosis and splanchnic venous thrombosis in recipients of Vaxzevria and Jcovden vaccines and the review focus on them. One year ago, thromboses in Vaxzevria recipients have been associated with thrombocytopenia in the presence of antibodies to platelet factor 4 and have been called vaccine-induced immune thrombotic thrombocytopenia (VITT). The incidence of VITT is equal to 9-31 events per one million doses of vaccines as evaluated by health agencies worldwide and is higher in female and young vaccine recipients. More recently, by using the European EudraVigilance database, it has been demonstrated that the incidence of thrombosis in recipients of adenovirus-based vaccines is 5–10 fold higher than that of VITT and 7–12 fold higher than observed in the recipients of Comirnaty, an mRNA-based vaccine, suggesting that adenovirus-based vaccines cause not only VITT but also thrombosis without thrombocytopenia (non-VITT thrombosis). The incidence of the vaccine-dependent non-VITT thrombosis is different in the adenovirus-based vaccines and the VITT/non-VITT incidence ratio depends on the severity of thrombosis and is inversely related to the age of the recipients. The possible causes and clinical implications of non-VITT thrombosis in vaccine recipients are discussed.

show abstract

Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background During the coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need for safe and effective COVID-19 vaccines to protect children and adolescents. This study aims to provide scientific evidence and recommendations for the application of COVID-19 vaccines in children and adolescents by analyzing the latest studies. Methods We systematically searched MEDLINE (accessed through PubMed), Embase, and Web of Science from January 1, 2020, to October 8, 2022. Eligible clinical trials, cohort studies, case‒control studies, and cross-sectional studies with extractable data were included in immunogenicity, effectiveness, and safety analyses. According to the heterogeneity, we chose a fixed-effect model (when I 2 ≤ 50) or a random-effects model (when I 2 > 50) to pool effect values. Results A total of 88 articles were included. The seroconversion rates after the first, second, and third doses of the vaccines were 86.10%, 96.52%, and 99.87%, respectively. After the first and second doses, vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 infection was 42.87% [95% confidence interval (CI) = 27.09%–58.65%] and 63.33% (95% CI = 52.09%–74.56%), respectively. After the first and second doses, VE against COVID-19 was 60.65% (95% CI = 44.80%–76.50%) and 75.77% (95% CI = 63.99%–87.56%), respectively. VE against hospitalization due to COVID-19 after the first and second doses was 72.74% (95% CI = 51.48%–94.01%) and 82.78% (95% CI = 75.78%–89.78%), respectively. The most common adverse events were injection site pain, fatigue/asthenia/tiredness, headache, myalgia/muscle pain, and chills. The incidence rate of myocarditis or pericarditis was 2.42/100,000 people. In addition, the subgroup analysis showed that children aged ≤ 5 years had the lowest incidence of adverse events, and the incidence rate of adverse events was higher for mRNA vaccines than for inactivated vaccines. Conclusions COVID-19 vaccines have good immunogenicity, effectiveness, and safety among children and adolescents. We recommend that children and adolescents be vaccinated as soon as possible to protect them and slow the spread of COVID-19. Supplementary Information The online version contains supplementary material available at 10.1007/s12519-022-00680-9.

show abstract

Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study

Cited by 19 publications

References 24 publications

Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study

Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study

Thrombotic events with or without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines

Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis

Contact Info

Product

Resources

About